Skip to Content

What is Braftovi used to treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on June 2, 2020.

Official Answer

by Drugs.com

Braftovi is used in combination with other drugs to treat patients with advanced melanoma and advanced colorectal cancer with BRAF gene mutations.

Braftovi is an oral small molecule BRAF kinase inhibitor.

Melanoma

Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.

Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.

Colorectal Cancer

Braftovi is used in combination with Erbitux (cetuximab), for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.

Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.

Related Medical Questions

Drug Information

Related Support Groups